Kruer, T. L., Quintana, A., Newman, H., Ferrall-Fairbanks, M., Zhang, L., McLemore, A., Neupane, S., Yang, Q., Dankyi, N. A., Balasis, M. E., Letson, C., Komrokji, R., Chaudhry, S., Totiger, T. M., Traina, J., Figueroa, M. E., Ryder, C. B., Cluzeau, T., Taylor, J., Sallman, D. A., Padron, E. (2025). XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignancies. Blood. https://doi.org/10.1182/blood.2025028803